|
JPH10130258A
(ja)
*
|
1996-10-10 |
1998-05-19 |
Eli Lilly & Co |
ベンゾ［ｂ］チオフェン化合物、中間体、製剤、および方法
|
|
EP0980367A4
(en)
|
1997-04-30 |
2003-03-19 |
Lilly Co Eli |
ANTITHROMBOTIC AGENTS
|
|
EP1011666A4
(en)
|
1997-04-30 |
2004-03-31 |
Lilly Co Eli |
ANTITHROMBOTIC AGENTS
|
|
CA2288224A1
(en)
|
1997-04-30 |
1998-11-05 |
Mary George Johnson |
Antithrombotic agents
|
|
EP0973517A4
(en)
|
1997-04-30 |
2002-07-24 |
Lilly Co Eli |
ANTITHROMBOTIC AGENTS
|
|
EP0980366B1
(en)
*
|
1997-04-30 |
2004-06-09 |
Eli Lilly And Company |
Antithrombotic agents
|
|
ES2210747T3
(es)
|
1997-05-01 |
2004-07-01 |
Eli Lilly And Company |
Agentes antitromboticos.
|
|
EP0988289A2
(en)
|
1997-06-05 |
2000-03-29 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds, their production and use
|
|
US6017914A
(en)
*
|
1997-09-03 |
2000-01-25 |
Eli Lilly And Company |
Benzo[b]thiophene compounds, intermediates, formulations, and methods
|
|
US6284756B1
(en)
|
1998-04-30 |
2001-09-04 |
Eli Lilly And Company |
Antithrombotic agents
|
|
US6166069A
(en)
*
|
1998-05-12 |
2000-12-26 |
American Home Products Corporation |
Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia
|
|
PT997460E
(pt)
*
|
1998-10-28 |
2003-03-31 |
Lilly Co Eli |
Compostos benzotiofenos como agentes antitromboticos e seus intermediarios
|
|
EP0997465B1
(en)
|
1998-10-30 |
2004-02-04 |
Eli Lilly And Company |
Azaindole derivatives and their use as antithrombotic agents
|
|
DE60008430T2
(de)
*
|
1999-11-19 |
2004-12-23 |
Eli Lilly And Co., Indianapolis |
Verbindungen mit antithrombotischer wirkung
|
|
JP2004531559A
(ja)
|
2001-05-22 |
2004-10-14 |
イーライ・リリー・アンド・カンパニー |
エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
|
|
EP1395563B1
(en)
|
2001-05-22 |
2006-03-29 |
Eli Lilly And Company |
2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
|
|
EP1465869B1
(en)
|
2001-12-21 |
2013-05-15 |
Exelixis Patent Company LLC |
Modulators of lxr
|
|
US7482366B2
(en)
|
2001-12-21 |
2009-01-27 |
X-Ceptor Therapeutics, Inc. |
Modulators of LXR
|
|
EA008024B1
(ru)
*
|
2002-07-22 |
2007-02-27 |
Эли Лилли Энд Компани |
Селективные модуляторы эстрогенных рецепторов, содержащие фенилсульфонильную группу
|
|
US7296361B2
(en)
*
|
2003-07-31 |
2007-11-20 |
University Of Pittsburgh |
Measuring device and method of measuring
|
|
ES2531660T3
(es)
|
2003-08-01 |
2015-03-18 |
Mitsubishi Tanabe Pharma Corporation |
Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
|
|
US8785403B2
(en)
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
|
AU2006212726C1
(en)
|
2005-02-14 |
2013-05-16 |
Bionomics Limited |
Novel tubulin polymerisation inhibitors
|
|
GB0507577D0
(en)
|
2005-04-14 |
2005-05-18 |
Novartis Ag |
Organic compounds
|
|
UY30730A1
(es)
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
|
RS56990B1
(sr)
|
2007-09-10 |
2018-05-31 |
Janssen Pharmaceutica Nv |
Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
|
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
|
HUE031375T2
(en)
|
2009-10-14 |
2017-07-28 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
SG10201506114UA
(en)
|
2010-05-11 |
2015-09-29 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
|
|
EP2697218B1
(en)
|
2011-04-13 |
2016-05-25 |
Janssen Pharmaceutica NV |
Process for the preparation of compounds useful as inhibitors of sglt2
|
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
（２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
|
|
CN104159900B
(zh)
|
2011-12-15 |
2016-08-24 |
拜耳知识产权有限责任公司 |
取代的苯并噻吩基-吡咯并三嗪及其在癌症治疗中的用途
|
|
JP6082033B2
(ja)
|
2012-02-23 |
2017-02-15 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ |
置換ベンゾチエニル−ピロロトリアジンおよびその使用
|
|
US10308871B2
(en)
|
2015-02-19 |
2019-06-04 |
Jnc Corporation |
Liquid crystal compound having benzothiophene, liquid crystal composition and liquid crystal display device
|
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
|
MX388576B
(es)
|
2016-06-07 |
2025-03-20 |
Jacobio Pharmaceuticals Co Ltd |
Derivados heterociclicos novedosos utiles como inhibidores de shp2.
|
|
EA202190196A1
(ru)
|
2017-03-23 |
2021-08-31 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
|
US20210393623A1
(en)
|
2018-09-26 |
2021-12-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
|